Cyclerion Therapeutics (NASDAQ: CYCN) saw its stock skyrocket on Wednesday, surging more than 300% during regular trading before extending gains in after-hours activity.
At its peak, CYCN shares briefly touched a new 52-week high of $8.48 before settling near $6.35 by the close. This rally lifted the company’s market capitalization to approximately $24.68 million. Over the past week alone, the stock has climbed nearly 294%, according to Google Finance data.
Merger Announcement Drives Momentum
The dramatic price movement followed Cyclerion’s confirmation of a definitive merger agreement with privately held Korsana Biosciences. According to the company’s press release, the transaction will be executed entirely as an all-stock deal.
Upon completion, the combined entity will operate under the Korsana Biosciences name and is expected to trade on Nasdaq under the ticker symbol “KRSA.”
Notably, the ownership structure heavily favors Korsana stakeholders. Cyclerion Therapeutics (NASDAQ: CYCN) shareholders are projected to retain approximately 1.5% of the merged company, while Korsana investors will control about 98.5%. This allocation underscores the transaction’s strategic nature, effectively positioning Korsana as the dominant entity.
$380 Million Financing Secured
In parallel with the merger, Korsana has secured significant financial backing to support its future operations. The company announced an oversubscribed private investment totaling roughly $380 million.
Fairmount and Venrock Healthcare Capital Partners are leading the financing round; it includes a mix of common stock and pre-funded warrants. Importantly, the funding is expected to close shortly before the merger is finalized.
Once completed, the combined company anticipates having sufficient capital to fund operations through 2029, thus providing a strong financial runway to advance its clinical pipeline.
Focus on Alzheimer’s Drug Development
With fresh capital in place, the merged entity will prioritize development of its lead candidate, KRSA-028, a treatment targeting Alzheimer’s disease.
The therapy is built on Korsana’s proprietary THETA™ platform, which combines transferrin receptor targeting with Fc engineering to improve drug delivery to the brain, a historically difficult target for similar treatments.
Looking ahead, several key milestones are planned. Phase 1 data from healthy volunteers is expected by mid-2027, followed by interim results later that year assessing amyloid plaque clearance in Alzheimer’s patients.
The treatment aims to enhance plaque removal while reducing safety risks. It is also designed with patient convenience in mind, utilizing a low-volume subcutaneous delivery method.
Leadership and Timeline for Completion
As integration plans move forward, leadership for the combined company has already been established. Korsana’s current CEO, Dr. Violin, will lead the organization, while its existing board will assume governance roles. Tomas Kiselak, a founding partner at Fairmount, is expected to serve as chairman.
Although both companies’ boards have approved the merger, the deal remains subject to several conditions, including shareholder approval, effectiveness of SEC registration, and regulatory clearance under the Hart-Scott-Rodino Act.
If all requirements are met, the transaction is expected to close in the third quarter of 2026. Wedbush Securities is advising Korsana, while Gemini Valuation Services is serving as Cyclerion’s advisor.
